Authors
Latest:
Talent Management Strategies for Post-Milestone GrowthInsights from Takeda, Jazz, Nestlé Health Sciences, Humana, and other healthcare executives
Latest:
Developing Patient-Focused Solutions: How a Multi-Modality Approach to Drug Discovery and Development is Driving Transformative InnovationWhen considering factors like disease biology and patient needs in drug discovery and development, the goal is to deliver effective and scalable treatments globally by balancing established approaches like small molecules or protein therapeutics with more complex modalities such as RNA, cell, and gene therapies.
Latest:
3 ASCO Insights for Pharma CommunicatorsThe world’s largest cancer research meeting, the American Society of Clinical Oncology (ASCO) Annual Meeting, recently convened in person in Chicago after two years of being held virtually. Sara Baker and Kristine Austria Fan of Marina Maher Communications provide their takeaways from the meeting.
Latest:
'Faster, Please': Key Challenges in Chemicals and Materials R&DCompanies must address myriad challenges to improve upon issues such as data quality and transparency, process efficiency, and artificial intelligence/machine learning preparedness.
Latest:
The Complementary Role of Real-World Evidence and Clinical Trials in Addressing Unmet Needs for IBD PatientsPatients with Crohn's disease and ulcerative colitis face a high disease burden.
Latest:
Omnichannel Marketing Challenges for European Life Sciences Companies: A Data Science PerspectiveAs EU brand leaders build their omnichannel customer engagement strategies, they need to address challenges in the European environment with a well-thought-out deployment plan.
Latest:
How Technology Can be Used to Improve AdherenceComprehensive dosage monitoring of topical treatments for mild to moderate psoriasis.
Latest:
Social Determinants of Health Data Evolution: Improve Access, Adherence and Achieve More Equitable OutcomesWebinar Date/Time: Tue, May 16, 2023 2:00 PM EDT
Latest:
A Pricing Revolution: The State OffensiveThe second of two articles summarizing the broad range of government efforts to control drug pricing focuses on state government efforts.
Latest:
Real-World Evidence Is Becoming a Pivotal Component in Chinese HealthcareIts use enables key processes such as early access, regulatory approval, and reimbursement listing.
Latest:
PREP Act Protections for COVID-19 Vaccine LiabilityHow PREP Act protections will apply to potential COVID-19 vaccine-related claims.
Latest:
Commercial Models for the Changing Life Sciences MarketLife sciences companies have an opportunity to craft a sales approach that resonates with clients, protects against future disruptions and stands out from the competition.
Latest:
Copay Adjustment Chess Match: What Will Payers Do Next?As new litigation looms in the debate over use of copay accumulator programs, a look at potential next moves for payers—and steps drug manufacturers should take to ward off cost-driven non-adherence.
Latest:
Digital Engagement is Only as Good as the First-Party Data It ProvidesFirst-party insights bridge marketing and sales to deliver better HCP experiences.
Latest:
Precision Medicine: Investments and Outcomes ExpectedPrecision medicine is now seen as a healthcare approach for both the present and the future, particularly with the explosion of personalized care delivery.
Latest:
AI’s Promise in Delivering on Patient-CentricityHow pharmaceutical companies can utilize AI at key stages of the treatment journey to enhance patient-centric engagement by increasing empathy and humanity in patient interactions.
Latest:
Redefining Care through Patient PartnershipAstraZeneca’s Niko Andre discusses the power of patient partnership in driving medical progress.
Latest:
How a “Push and Pull” Approach Can Maximize Innovation Value through HTAsHow can companies adapt their single evidence package at launch into multiple, tailored versions for HTAs that vary across different countries and regions?
Latest:
Modular Approaches are Opening the Portal to Better HCP EngagementPortals are finally a viable channel as life sciences companies shift to modular to build their digital ecosystems, create and approve content, and deliver omnichannel experiences.
Latest:
Congress, Have a More Thoughtful, Bipartisan Pandemic Post-MortemCongress and our nation’s public health officials should take the current moment to self-reflect and resolve challenges with public confidence in our public and scientific institutions.
Latest:
Succession Attack Plan: Get Strategic with Your Critical RolesOutlining four considerations for biopharma companies in ensuring that their approach to replacing and filling key leadership positions is more truly aligned with future goals in business delivery and risk management.
Latest:
Beyond the Scrubs: Understanding Healthcare Providers as People for Increased EngagementThe benefits of adopting a humanized approach to healthcare provider marketing extend across the healthcare spectrum, enhancing engagement rates, brand loyalty, and marketing ROI, while also driving better outcomes for patients.
Latest:
Why Culture, Ethics, and Compliance Are More Important Than Ever Post-COVIDIf the COVID-19 crisis represents an unprecedented opportunity for pharma to strengthen its public reputation, it also poses enormous risks if things go wrong, writes Professor Guido Palazzo.
Latest:
FDA’s Guidance on Using RWD in Evidence Generation Is a Big Step ForwardPractices to ensure accuracy in selected datasets.
